June 5, 2008 — A case study concerning the Axiom Worldwide’s DRX9000, published in the 2008 issue of the European Musculoskeletal Review, was mentioned in an online newsletter from the Food and Drug Administration (FDA).
The FDA news item was headlined, “Axiom Case Study Yields Favorable Findings with Back Pain Device.”
It read, in part, “A study evaluating Axiom Worldwide’s DRX9000 true nonsurgical spinal decompression system has produced positive results. … The study chronicled a patient who underwent 22 treatments with the device over a seven-week period and reported significant pain relief at the end of the study.”
The study can be downloaded at http://axiomworldwide.com/research.
Source: Axiom WorldWide, www.axiomworldwide.com
Related Posts
Study shows Traumeel as effective treatment for musculoskeletal disorders- Multi Radiance Medical Super Pulsed Lasers receive FDA clearance for neck and shoulder pain
- Axiom Worldwide wins court case against HTRD, Excite Medical, Saleem Musallam
- ZyCal Bioceuticals Healthcare announces self-affirmed GRAS status for Cyplexinol
- AHPA asks FDA to withdraw labeling guidance
- FDA warns epidural injections of corticosteroids for back and neck pain may cause severe neurological effects
